Work

Dupilumab: Evaluating its role in atopic dermatitis, prurigo nodularis, eczemas, urticaria, alopecia areata and vesiculobullous disorders

Year: 2024

Type: article

Abstract: Dupilumab is a fully human monoclonal IgG4 antibody that targets IL-4 and IL-13 signaling pathways. It is approved by the US-FDA for the treatment of atopic dermatitis and prurigo nodularis. Besides, it has shown efficacy in various off-label dermatologic conditions. This review will elaborate on the utility of dupilumab in atopic dermatitis, prurigo nodularis, eczemas, urticaria, alopecia areata and vesiculobullous disorders.

Source: Journal of Skin and Sexually Transmitted Diseases

DOI: 10.25259/jsstd_45_2024

Authors: Aditya Kumar Bubna, Vinayak Viplav

Language: English

Topic: Dermatology and Skin Diseases

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4404651210

FWCI:

Cites: 155

Cited by:

Related to: 10